


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

77. (Currently amended) A compound of the formula:



or a pharmaceutically acceptable salt or complex thereof,

wherein alkyl is a  $\text{C}_4\text{-C}_6$   $\text{C}_3\text{-C}_6$  hydrocarbon having  $\text{sp}^2$  and/or  $\text{sp}^3$  hybridization and comprising a cycloaliphatic ring;

each Y is independently an aromatic or cycloaliphatic ring or ring system;

each R is independently a hydrogen,  $\text{CF}_3$ ,  $\text{CF}_2\text{H}$ ,  $\text{CFH}_2$ ,  $\text{CH}_2\text{CF}_3$ , phenyl or  $\text{C}_1\text{-C}_{10}$  linear, branched, cyclic, fused cyclic and/or bicyclic alkyl having  $\text{sp}$ ,  $\text{sp}^2$  and/or  $\text{sp}^3$  hybridization;

each X is independently a hydrogen, fluoro, chloro, bromo, iodo, -OR, -NR<sub>2</sub>, -SR, -S(O)R, -S(O)<sub>2</sub>R, cyano, nitro, -C(O)R, -OC(O)R, -C(O)OR, -N(R)-C(O)R or -C(O)NR<sub>2</sub>;

and


each m is independently 0, 1, 2, 3, 4, 5, 6 or 7.

78. (Currently amended) The compound of Claim 77 or a pharmaceutically acceptable salt or complex thereof, wherein Alkyl is  $\text{C}_4\text{-C}_6$  a  $\text{C}_4\text{-C}_6$  hydrocarbon having  $\text{sp}^2$  or  $\text{sp}^3$  hybridization which is cyclic, and further comprises linear or branched moieties, or a combination thereof.

79. (Currently amended) The compound of Claim ~~78~~ 77 or a pharmaceutically acceptable salt or complex thereof, wherein Alkyl is cyclopropyl, cyclohexyl or cyclopropylmethyl.

80. (Currently amended) The compound of Claim 79 or a pharmaceutically acceptable salt or complex thereof, wherein each  $\text{Ar}^1$   $\text{Y}^1$  is independently a phenyl, 1- or 2-naphthyl.

81. (Currently amended) The compound of claim 77 having the formula



or a pharmaceutically acceptable salt or complex thereof, wherein  $\text{Ar}^1$   $\text{Y}^1$  and  $\text{Ar}^2$   $\text{Y}^2$  are each independently an aromatic or cycloaliphatic ring or ring system; and


$\text{R}_1$  and  $\text{R}_2$  are each independently a hydrogen,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{H}$ ,  $-\text{CFH}_2$ ,  $-\text{CH}_2\text{CF}_3$ , phenyl or  $\text{C}_1\text{-C}_{10}$  linear, branched, cyclic, fused cyclic and/or bicyclic alkyl having  $\text{sp}$ ,  $\text{sp}^2$  and/or  $\text{sp}^3$  hybridization.

82. (Currently amended) The compound of Claim 81 or a pharmaceutically acceptable salt or complex thereof, wherein  $\text{Ar}^1$  and  $\text{Ar}^2$   $\text{Y}^1$  and  $\text{Y}^2$  are each independently a phenyl, or 1- or 2-naphthyl.

83. (Currently amended) The compound of Claim 82 or a pharmaceutically acceptable salt or complex thereof, wherein  $\text{Ar}^1$   $\text{Y}^1$  is independently a phenyl or 2-naphthyl; and  $\text{Ar}^2$   $\text{Y}^2$  is independently a phenyl or 1-naphthyl.

84. (Previously presented) The compound of Claim 83 or a pharmaceutically acceptable salt or complex thereof, wherein  $\text{R}_1$  is a methyl; and  $\text{R}_2$  is a hydrogen.

85. (Previously presented) The compound of Claim 77 which is



or a pharmaceutically acceptable salt or complex thereof.

86. (Cancelled)

87. (New). The compound of claim 77 or a pharmaceutically acceptable salt or complex thereof wherein the cycloaliphatic ring is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

88. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a compound of any one of Claims 77-87 or a pharmaceutically acceptable salt or complex thereof.